![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
KMPH Diminishing Returns have widen at $-0.19 per share in the most recent fiscal period, although its Revenues surged by 46.26 % to $
2.87 millions from the same reporting period a year before.
In the previous reporting period KMPH realized Revenue of $1.30 millions and $-0.70 per share.
For the fiscal third quarter of 2022 Kempharm Inc realized net shortfall of $-6.616 million, bigger than $-1.759 million a year ago.
Kempharm Inc is expected to report next financial results on March 29, 2023.